Exclusive Summary

• - Patents have expired and markets are fully genericized (US/EU since 2011–2013), enabling rapid registration, distribution, and tech transfer entry.
• - Strong, recurring demand in bone metastases and malignancy-associated hypercalcemia, with millions of treatment opportunities annually; listed on WHO EML and recommended by ASCO/ESMO/NCCN.
• - 70–95% cost savings vs originator and substantial advantage vs denosumab; room-temperature storage and 15-minute infusion simplify hospital use and tenders.
• - BP/USP/EP-compliant API supports multi-region filings; CTD support and TT enable local manufacturing for access and tender eligibility.
• - Despite crowded competition, differentiation is possible via reliable supply, robust regulatory package, Q12-week dosing strategy, and TT localization (Vietnam requires direct local partner, no China agency).